Neoplasm Clinical Trial
Official title:
Linkage of Medicaid Enrollment Lnformation to Surveillance, Epidemiology and End Results Data
Verified date | May 2020 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
The SEER database collects data about people with cancer. SEER stands for Surveillance,
Epidemiology, and End Results. Medicaid is a kind of health insurance. It is for people who
have low income or serious medical needs. Many studies have shown that Medicaid recipients
with cancer are more likely to be diagnosed later in the disease than people with other
insurance. They are also less likely to get treatment. Researchers want to compare Medicaid
data and SEER data. They want to make this available to other scientists.
Objectives:
To link people in the SEER database to Medicaid data for the years around their cancer
diagnosis. To create a file that contains SEER case numbers linked to Medicaid numbers.
Eligibility:
No people are enrolled in this study.
Design:
The SEER finder file will be securely uploaded to the CMS Data Center.
The finder file will be matched against the Medicaid Personal Summary file at the CMS Data
Center.
If participants appear in both the SEER file and Medicaid file, their data will be extracted.
The dates of Medicaid data will be compared with the SEER date of diagnosis. Researchers will
see if the Medicaid dates fall in certain periods. These are 12 months before, the month of,
and 11 months after diagnosis.
If participants are eligible for Medicaid for these periods, a flag will be created in the
file. It will note the participants is eligible and why.
The SEER finder file will be destroyed.
The only data saved will be:
Each participant's unique random SEER case number linked to their Medicaid number
Monthly flags about Medicaid eligibility
Status | Completed |
Enrollment | 3217145 |
Est. completion date | May 20, 2020 |
Est. primary completion date | May 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 120 Years |
Eligibility |
- INCLUSION: - Cancer Diagnosis - Medicaid Member - Registered within the SEER Program EXCLUSION: -None |
Country | Name | City | State |
---|---|---|---|
United States | National Cancer Institute (NCI) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Link persons included in the Surveillance, Epidemiology and End Results (SEER) data to Medicaid enrollment information | 7 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT00199836 -
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
|
Phase 1 | |
Completed |
NCT01672944 -
Evaluating Biobanking Educational Tools
|
N/A | |
Not yet recruiting |
NCT02226289 -
Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
|
Phase 2 | |
Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Completed |
NCT02747342 -
A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
|
Phase 1 | |
Completed |
NCT02536586 -
A Study of LY3023414 in Japanese Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02309164 -
The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN).
|
N/A | |
Completed |
NCT02394821 -
Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide
|
Phase 3 | |
Completed |
NCT01457196 -
Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions
|
N/A | |
Completed |
NCT00143533 -
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05450562 -
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00001835 -
Oxaliplatin in Cancer Patients With Impaired Kidney Function
|
Phase 1 | |
Completed |
NCT00001341 -
A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease
|
Phase 1 | |
Completed |
NCT01425008 -
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05101798 -
The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial
|
Phase 2 | |
Completed |
NCT01920061 -
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
|
Phase 1 | |
Terminated |
NCT03251924 -
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02851706 -
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
|